Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after acute myocardial infarction

Coronary Artery Disease

Volumn 19, Issue 8, 2008, Pages 597-602

  Huang, Shao Sung ^a   Huang, Po Hsun ^a,b,c   Chen, Ying Hwa ^a,c   Sung, Shih Hsien ^a   Chiang, Kuang Hsing ^a   Chen, Jaw Wen ^a,c   Lin, Shing Jong ^a,b,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Institute of Clinical Medicine   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Acute myocardial infarction; Cardiovascular events; Heparin cofactor II

Indexed keywords

DERMATAN SULFATE; HEPARIN COFACTOR II; THROMBIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; FEMALE; HEART DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVASCULARIZATION; UNSTABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CORONARY ARTERY BYPASS; DISEASE-FREE SURVIVAL; FEMALE; HEPARIN COFACTOR II; HOSPITAL MORTALITY; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT READMISSION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; TIME FACTORS; UP-REGULATION;

EID: 56849120713     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3283155579     Document Type: Article

References (23)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathophysiology of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326:242-250.
2. DiCorleto PE. Cellular mechanisms of atherogenesis. Am J Hypertens 1993; 6:314S-318S.
3. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 1992; 90:1614-1821.
4. Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258:6713-6716.
5. Tollefsen DM. Insight into the mechanism of action of heparin cofactor II. Thromb Haemost 1995; 74:1209-1214.
6. Sie P, Dupouy D, Pichon J, Boneu B. Constitutional heparin co-factor II deficiency associated with recurrent thrombosis. Lancet 1985; 2:414-416.
7. Tran TH, Marbel GA, Duckert F. Association of hereditary heparin co-factor II deficiency with thrombosis. Lancet 1985; 2:413-414.
8. Takamori N, Azuma H, Kato M, Hashizume S, Aihara K, Akaike M, et al. High plasma heparin cofactor II activity is associated with reduced incidence of instent restenosis after percutaneous coronary intervention. Circulation 2004; 109:481-486.
9. Aihara K, Azuma H, Takamori N, Kanagawa Y, Akaike M, Fujimura M, et al. Heparin cofactor II is a novel protective factor against carotid atherosclerosis in elderly individuals. Circulation 2004; 109:2761-2765.
10. Huang PH, Leu HB, Chen JW, Wu TC, Lu TM, Yu-An Ding P, et al. Decreased heparin cofactor II activity is associated with impaired endothelial function determined by brachial ultrasonography and predicts cardiovascular events. Int J Cardiol 2007; 114:152-158.
11. He L, Vicente CP, Westrick RJ, Eitzman DT, Tollefsen DM. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest 2002; 109:213-219.
12. Narayanan S. Multifunctional roles of thrombin. Ann Clin Lab Sci 1999; 29:275-280.
13. Bar-Shavit R, Kahn A, Wilner GD, Fenton JW II. Monocyte Chemotaxis: stimulation by specific exosite region in thrombin. Science 1983; 220:728-731.
14. Chen LB, Buchanan JM. Mitogenic activity of blood components: I. Thrombin and prothrombin. Proc Natl Acad Sci USA 1975; 72:131-135.
15. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW 2nd, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993; 91:94-98.
16. Liu L, Dewar L, Song Y, Kulczycky M, Blajchman MA, Fenton JW 2nd, et al. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo. Thromb Haemost 1995; 73:405-412.
17. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86:2839-2843.
18. Schafer AI. Vascular endothelium: in defense of blood fluidity. J Clin Invest 1997; 99:1143-1144.
19. Schillinger M, Exner M, Sabeti S, Mlekusch W, Amighi J, Handler S, et al. High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stenting. Thromb Haemost 2004; 92: 1108-1113.
20. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234.
21. Schneider DJ, Sobel BE. Diabetes and thrombosis. In: Johnstone MT, Veves A, editors. Diabetes and cardiovascular disease. Totowa, New Jersey: Humana Press; 2001. pp. 149-168.
22. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000; 102:2180-2184.
23. Purushothaman KR, Fuster V, O'Connor W, Moreno PR. Neovascularization, inflammation and intra-plaque hemorrhage are increased in advanced human atherosclerosis from patients with diabetes mellitus. Circulation 2003; 108:459.